Azatirel 100mg Injection

Bone marrow cancer

Some patients experience various symptoms which resolve on their own but some may require proper medical attention. Some of the side effects of Azatirel 100mg Injection are:

● Injection site reaction (pain, swelling or redness)
● Nausea
● Vomiting
● Weakness
● fever
● Chills
● Diarrhea
● Constipation
● Bruise

Azatirel 100mg Injection is an anti-cancer medication. Doctor recommended taking the injection with or without food at the fixed time. The injection is given once daily and after some time cycle repeats every few weeks. Total duration may involve multiple duration over months, depending on the response. The exact dose and number of days in each cycle are determined only by the oncologist. Do not self administer this medication under any circumstances.

Bone marrow cancer disrupts the production of healthy cells and weakens the immune system that decreases the body's ability to fight with the infection. Azatirel tablet is a nucleoside metabolic inhibitor which works by inhibiting the cancer cells in DNA and prevent the body from multiplication of cancer cells. The medicine kills abnormal cells while allowing normal cells to recover by improving overall bone marrow function.

• Issa, J. P. J., Kantarjian, H. M., & Kirkpatrick, P. (2005). Azacitidine. Nature Reviews Drug Discovery, 4(4), 275-276.
• Kaminskas, E., Farrell, A. T., Wang, Y. C., Sridhara, R., & Pazdur, R. (2005). FDA drug approval summary: azacitidine (5-azacytidine, Vidaza™) for injectable suspension. The oncologist, 10(3), 176-182.
• Glover, A. B., & Leyland-Jones, B. (1987). Biochemistry of Azacitidine: A Review¹. Cancer treatment reports, 71(10-12), 959.
• DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., ... & Pratz, K. W. (2020). Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New England journal of medicine, 383(7), 617-629.
• Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L. S., Lee, S. L., ... & Pazdur, R. (2005). Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical cancer research, 11(10), 3604-3608.